The Matrixx Zicam Verdict - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Matrixx Zicam Verdict
The authors summarize the Matrixx Initiatives, Inc. v. Siracusano case's implications for industry.

Pharmaceutical Technology
Volume 35, Issue 10, pp. 118-122

Implications for the pharmaceutical industry

The Supreme Court's discussions of "bright-line" decision rules and the "total mix"of information applies to the use of statistical analysis of quality assurance and manufacturing data. Without too much difficulty, the Supreme Court's position could apply equally to stability studies, assay validation, process validation, design space, and process capability.

Anyone who has hosted an FDA inspection knows that an investigator need not wait for a control chart to exceed one or more of the classic "out-of-control" signals before beginning a review of suspicious current and historical data.

Sampling-plan acceptance should not be used as a defense for accepting some lots when it is clear from all the available information that the defect rate is higher than desired for the process as a whole. Waiting for a statistically significant event before evaluating a trend simply pushes the problem down the road; such an approach is also inconsistent with the concept of quality by design.

Manufacturers should be looking at the total mix of information throughout process design, process qualification, and process verification. FDA's guidance for industry on Process Validation: General Principles and Practices, issued in January 2011, makes clear that understanding the manufacturing process and potential variations—that is, the total mix of information—is essential for product quality. Interestingly, the FDA process-validation guidance makes no mention of statistical significance. The document does refer to statistical confidence several times, but only in a general sense. It does not suggest or require a specific confidence level.

As stated above, statistical significance is only the determination that the difference we observe is larger than we would expect by random chance alone given the available estimate of variability. It is not necessarily truth, fact, or causation. It is only one tool for understanding all of the available information. FDA expects pharmaceutical manufacturers to use science-based reasoning to determine which tools are appropriate for evaluating any given issue.

In the laboratory. An out-of-specification (OOS) determination is the result of comparing a single reportable value collected at a specific point in time with a specification. Statistical significance has no role in this determination, nor does practical significance. A reportable result is either within specification or OOS. Thus, the Matrixx case has little or no implication for OOS determinations.

A determination of out-of-trend (OOT) is the result of comparing one or more reportable results collected over a time period with a statistically defined model or to statistically summarize those historical data. If a trend is large enough to be of practical importance to an experienced analyst, then data should be reviewed even if they do not rise to the level of statistical significance. If the data are statistically significant, then chance is ruled out and a cause-and-effect relationship is supported but not proven. This position is supported by Matrixx, in that a lack of statistical significance does not justify failing to investigate a change in the data that could be of practical importance. Statistical significance cannot be used, to quote the Supreme Court, as a single "bright-line" decision rule to the exclusion of other sources of supporting information. The evaluation of OOT data must be an evaluation of the "total mix" of information.

Product liability lawsuits. Given that the underlying facts in Matrixx relate to adverse drug events, it is reasonable to ask whether the Supreme Court's decision has any bearing on product liability lawsuits. Although the case does not appear to change the Supreme Court's view of the standard for causation (i.e., that the product "more likely than not" caused the injury, and that statistical significance is not necessary to prove such a claim), it does seem to reinforce the Supreme Court's holding in an earlier decision, Wyeth v. Levine, regarding a drug manufacturer's responsibility to act upon new information about adverse events (24).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here